Enticed through the immense marketplace opened through GLP-1 weight reduction medication Wegovy and Zepbound, a handful of biotech firms are looking to increase next-generation, longer-lasting treatments in keeping with an overly other method: RNA interference.
This Nobel Prize-winning science works through degrading the organic blueprints that RNA use to make proteins — with out the genetic directions, the difficult proteins are by no means made and the gene is largely muted.
If the corporations prevail, it will be an important shift within the weight problems remedy revolution, clear of weekly medication concentrated on hormones to drugs that may be given a lot much less often — two times a yr and even much less — and pinpoint genetic members to weight.
STAT+ Unique Tale
Have already got an account? Log in
This newsletter is unique to STAT+ subscribers
Free up this text — plus day-to-day protection and research of the biotech sector — through subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
Person plans
Staff plans
View All Plans
Get limitless get right of entry to to award-winning journalism and unique occasions.
Subscribe
